Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards, St. Jude Transcatheter Valve Programs Mark Progress

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences and St. Jude Medical each marked notable milestones in the closely watched transcatheter aortic valve space last week.

You may also be interested in...



Regulatory News In Brief

Human factors guidance

Regulatory News In Brief

Human factors guidance

Getting Set For Sapien: With Data In, Discussion Moves To Adoption Dynamics

With all the major clinical data from Edwards Lifesciences' closely watched PARTNER trial now out in the open, there is little doubt among clinicians and industry analysts that transcatheter aortic heart valve replacements will be a U.S. commercial reality in the near term.

Related Content

UsernamePublicRestriction

Register

MT030238

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel